Genedrive (AIM:GDR), the AIM-listed point-of-care pharmacogenetic testing company, said its Genedrive MT-RNR1 ID Kit has been implemented at Erasmus MC University Medical Center in Rotterdam, effective from 3 August.
The test screens newborns for a genetic variant that puts them at risk of profound, irreversible hearing loss from aminoglycoside antibiotics, commonly used to treat suspected sepsis.
Erasmus MC's neonatal intensive care unit treats approximately 750 babies a year and is funding the rollout through its Pharmacogenetics International Expert Center, led by Professor Dr Ron H.N. van Schaik.
Van Schaik, head of the hospital's clinical chemistry department, said rapid testing lets clinicians identify at-risk babies "before treatment is given, supporting informed prescribing decisions without delaying urgently needed antibiotic treatment." He also noted Erasmus MC is the first Dutch medical centre to embed the technology into routine neonatal care.
Genedrive chief executive Gino Miele said the deployment "strengthens our presence in Europe and builds on the growing adoption of our technology in the UK and internationally."
The kit is already in routine use across more than 20 neonatal intensive care units in the UK and elsewhere, with clinical and commercial activity ongoing across Europe and the Middle East.
News Intelligence what this means for the company
Genedrive's MT-RNR1 ID Kit has been adopted at Erasmus MC, the Netherlands' first hospital to embed the test into routine neonatal care, treating ~750 babies annually. The deployment extends the company's European footprint beyond its established UK presence (already in use across 20+ neonatal intensive care units) and validates the clinical case for rapid pharmacogenetic screening before aminoglycoside treatment—a use case backed by UK clinical guideline and recently cited by Parliament.
This is incremental geographic expansion of an already-deployed product into a new market, not a new indication or technology. It demonstrates real-world traction in continental Europe but does not materially alter the company's near-term revenue trajectory—expected total income of ~£1.4m for FY26—or resolve the fundamental challenge of scaling a niche diagnostic test across fragmented healthcare systems.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
